These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises. Van Langendonckt A; Donnez J; Defrère S; Dunselman GA; Groothuis PG Mol Hum Reprod; 2008 May; 14(5):259-68. PubMed ID: 18430758 [TBL] [Abstract][Full Text] [Related]
24. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. Bottsford-Miller JN; Coleman RL; Sood AK J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289 [TBL] [Abstract][Full Text] [Related]
25. Metronomic chemotherapy for cancer treatment: a decade of clinical studies. Romiti A; Cox MC; Sarcina I; Di Rocco R; D'Antonio C; Barucca V; Marchetti P Cancer Chemother Pharmacol; 2013 Jul; 72(1):13-33. PubMed ID: 23475105 [TBL] [Abstract][Full Text] [Related]
26. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents. Siemann DW Cancer Treat Rev; 2011 Feb; 37(1):63-74. PubMed ID: 20570444 [TBL] [Abstract][Full Text] [Related]
27. Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic. Spear MA; LoRusso P; Mita A; Mita M Curr Drug Targets; 2011 Dec; 12(14):2009-15. PubMed ID: 21777190 [TBL] [Abstract][Full Text] [Related]
28. Synopsis of angiogenesis inhibitors in oncology. Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576 [TBL] [Abstract][Full Text] [Related]
29. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy. Abdollahi A; Folkman J Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178 [TBL] [Abstract][Full Text] [Related]
30. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Glade Bender J; Cooney EM; Kandel JJ; Yamashiro DJ Drug Resist Updat; 2004; 7(4-5):289-300. PubMed ID: 15533766 [TBL] [Abstract][Full Text] [Related]
31. Vascular-disrupting agents in oncology. Mita MM; Sargsyan L; Mita AC; Spear M Expert Opin Investig Drugs; 2013 Mar; 22(3):317-28. PubMed ID: 23316880 [TBL] [Abstract][Full Text] [Related]
33. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy. Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804 [TBL] [Abstract][Full Text] [Related]
34. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related]
36. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist. Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562 [TBL] [Abstract][Full Text] [Related]
37. Vascular targeting therapy: potential benefit depends on tumor and host related effects. Horsman MR; Bohn AB; Busk M Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608 [TBL] [Abstract][Full Text] [Related]
38. Small molecule vascular disrupting agents: potential new drugs for cancer treatment. Cai SX Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055 [TBL] [Abstract][Full Text] [Related]
39. Angiogenesis inhibitors. Drug selectivity and target specificity. Kesisis G; Broxterman H; Giaccone G Curr Pharm Des; 2007; 13(27):2795-809. PubMed ID: 17897024 [TBL] [Abstract][Full Text] [Related]
40. Resistance to antiangiogenic therapies. Bartolotti M; Franceschi E; Poggi R; Tosoni A; Di Battista M; Brandes AA Future Oncol; 2014 Jun; 10(8):1417-25. PubMed ID: 25052752 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]